We evaluated the immunogenicity and safety of a @-dose infant/toddler regimen of MenACWY-CRM given at @ , @ , @ , and @ months of age concomitantly with pentavalent diphtheria-tetanus-acellular pertussis-Hemophilus influenzae type b-inactivated poliovirus-combination vaccine ( DTaP-IPV/Hib ) , hepatitis B vaccine ( HBV ) , @ - or @-valent conjugate pneumococcal vaccine ( PCV ) , and measles , mumps , and rubella vaccine ( MMR ) .